Cyclooxygenase/lipoxygenase shunting lowers the anti-cancer effect of cyclooxygenase-2 inhibition in colorectal cancer cells

World Journal of Surgical Oncology

Volumn 10, Issue , 2012, Pages

  Ganesh, Radhakrishnan ^a   Marks, Daniel J B ^a   Sales, Kevin ^a   Winslet, Marc C ^a   Seifalian, Alexander M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Apoptosis; Colorectal cancer; Cyclooxygenase; Eicosanoids; Lipoxygenase

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; CASPASE 3; CASPASE 7; CYCLOOXYGENASE 2; DOUBLE STRANDED DNA; LEUKOTRIENE B4; LIPOCORTIN 5; PROPIDIUM IODIDE; PROSTAGLANDIN E2; ROFECOXIB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARACHIDONIC ACID METABOLISM; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; COLORECTAL CANCER; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN SECRETION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; ARACHIDONATE 5-LIPOXYGENASE; ARACHIDONIC ACID; BLOTTING, WESTERN; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LEUKOTRIENE B4; TUMOR CELLS, CULTURED;

EID: 84871462349     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-10-200     Document Type: Article

References (41)

1. Hamilton SR. The adenoma-adenocarcinoma sequence in the large bowel: variations on a theme. J Cell Biochem 1992, Suppl. 16G:41-46.
2. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 1981, 66:1191-1308.
3. van Duijnhoven FJ, Bueno-De-Mesquita HB, Ferrari P, Jenab M, Boshuizen HC, Ros MM, et al. Fruit, vegetables, and colorectal cancer risk: the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 2009, 89:1441-1452. 10.3945/ajcn.2008.27120, 19339391.
4. Terhaar Sive Droste JS, Tuynman JB, Van Dullemen HM, Mulder CJ. Chemoprevention for colon cancer: new opportunities, fact or fiction?. Scand J Gastroenterol 2006, Suppl 158:158-164.
5. Lamprecht SA, Lipkin M. Chemoprevention of colon cancer by calcium, vitamin D and folate: molecular mechanisms. Nat Rev Cancer 2003, 3:601-614. 10.1038/nrc1144, 12894248.
6. Pardi DS, Loftus EV. Kremers WK, Keach J, Lindor KD: Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003, 124:889-893. 10.1053/gast.2003.50156, 12671884.
7. Taylor ML, Wells BJ, Smolak MJ. Statins and cancer: a meta-analysis of case- control studies. Eur J Cancer Prev 2008, 17:259-268. 10.1097/CEJ.0b013e3282b721fe, 18414198.
8. Krishnamoorthy S, Honn KV. Eicosanoids in tumor progression and metastasis. Subcell Biochem 2008, 49:145-168. 10.1007/978-1-4020-8831-5_6, 18751911.
9. De Vries CE, van Noorden CJ. Effects of dietary fatty acid composition on tumor growth and metastasis. Anticancer Res 1992, 12:1513-1522.
10. Claria J. Regulation of cell proliferation and apoptosis by bioactive lipid mediators. Recent Pat Anticancer Drug Discov 2006, 1:369-382.
11. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000, 69:145-182. 10.1146/annurev.biochem.69.1.145, 10966456.
12. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995, 55:3785-3789.
13. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993, 122:518-523.
14. Sun Y, Tang XM, Half E, Kuo MT, Sinicrope FA. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res 2002, 62:6323-6328.
15. Tang X, Sun YJ, Half E, Kuo MT, Sinicrope F. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res 2002, 62:4903-4908.
16. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, Tiano HF, Morham SG, Smithies O, Langenbach R. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000, 60:4705-4708.
17. Prescott SM, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 2000, 1470:M69-M78.
18. Saini MK, Sharma P, Kaur J, Sanyal SN. The cyclooxygenase-2 inhibitor etoricoxib is a potent chemopreventive agent of colon carcinogenesis in the rat model. J Environ Pathol Toxicol Oncol 2009, 28:39-46. 10.1615/JEnvironPatholToxicolOncol.v28.i1.40, 19392653.
19. Wang L, Chen W, Xie X, He Y, Bai X. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer. Exp Oncol 2008, 30:42-51.
20. Soumaoro LT, Iida S, Uetake H, Ishiguro M, Takagi Y, Higuchi T, Yasuno M, Enomoto M, Sugihara K. Expression of 5-lipoxygenase in human colorectal cancer. World J Gastroenterol 2006, 12:6355-6360.
21. Melstrom LG, Bentrem DJ, Salabat MR, Kennedy TJ, Ding XZ, Strouch M, Rao SM, Witt RC, Ternent CA, Talamonti MS, Bell RH, Adrian TA. Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clin Cancer Res 2008, 14:6525-6530. 10.1158/1078-0432.CCR-07-4631, 18927292.
22. Park SW, Heo DS, Sung MW. The shunting of arachidonic acid metabolism to 5-lipoxygenase and cytochrome p450 epoxygenase antagonizes the anti-cancer effect of cyclooxygenase-2 inhibition in head and neck cancer cells. Cell Oncol (Dordr) 2012, 35:1-8.
23. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. NSAID-induced urticaria and angioedema: a reappraisal of its clinical management. Am J Clin Dermatol 2002, 3:599-607. 10.2165/00128071-200203090-00002, 12444802.
24. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991, 101:635-639.
25. Vinogradova Y, Hippisley-Cox J, Coupland C, Logan RF. Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case- control study. Gastroenterology 2007, 133:393-402. 10.1053/j.gastro.2007.05.023, 17681160.
26. Trujillo MA, Garewal HS, Sampliner RE. Nonsteroidal antiinflammatory agents in chemoprevention of colorectal cancer. At what cost?. Dig Dis Sci 1994, 39:2260-2266. 10.1007/BF02090382, 7924753.
27. Kerr DJ, Dunn JA, Langman MJ, Smith JL, Midgley RS, Stanley A, Stokes JC, Julier P, Iveson C, Duvvuri R, McConkey CC, . VICTOR Trial Group Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 2007, 357:360-369. 10.1056/NEJMoa071841, 17652651, VICTOR Trial Group.
28. Schiffmann S, Maier TJ, Wobst I, Janssen A, Corban-Wilhelm H, Angioni C, Geisslinger G, Grösch S. The anti-proliferative potency of celecoxib is not a class effect of coxibs. Biochem Pharmacol 2008, 76:179-187. 10.1016/j.bcp.2008.04.017, 18547544.
29. Wobst I, Schiffmann S, Birod K, Maier TJ, Schmidt R, Angioni C, Geisslinger G, Grösch S. Dimethylcelecoxib inhibits prostaglandin E2 production. Biochem Pharmacol 2008, 76:62-69. 10.1016/j.bcp.2008.04.008, 18508034.
30. Ma D, Liu M, Wang AP, Yang H. Cycloxygenase-2 is essential for the survival and proliferation of gastric cancer cells. Cell Biochem Biophys 2011, 61:637-641. 10.1007/s12013-011-9249-6, 21830126.
31. Hsi LC, Baek SJ, Eling TE. Lack of cyclooxygenase-2 activity in HT-29 human colorectal carcinoma cells. Exp Cell Res 2000, 256:563-570. 10.1006/excr.2000.4863, 10772828.
32. Tavolari S, Bonafe M, Marini M, Ferreri C, Bartolini G, Brighenti E, Manara S, Tomasi V, Laufer S, Guarnieri T. Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. Carcinogenesis 2008, 29:371-380.
33. Kannan RY, Salacinski HJ, Sales KM, Butler PE, Seifalian AM. The endothelialization of polyhedral oligomeric silsesquioxane nanocomposites: an in vitro study. Cell Biochem Biophys 2006, 45:129-136. 10.1385/CBB:45:2:129, 16757813.
34. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 2007, 121:2381-2386. 10.1002/ijc.23192, 17893868.
35. Gao P, Guan L, Zheng J. Role of leukotriene B4 in celecoxib-mediated anticancer effect. Biochem Biophys Res Commun 2010, 402:308-311. 10.1016/j.bbrc.2010.10.022, 20937254.
36. Romano M, Claria J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J 2003, 17:1986-1995. 10.1096/fj.03-0053rev, 14597668.
37. Ye YN, Wu WK, Shin VY, Bruce IC, Wong BC, Cho CH. Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis 2005, 26:827-834. 10.1093/carcin/bgi012, 15637091.
38. Hong SH, Avis I, Vos MD, Martinez A, Treston AM, Mulshine JL. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res 1999, 59:2223-2228.
39. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett 2002, 531:278-284. 10.1016/S0014-5793(02)03535-4, 12417326.
40. Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, Shiff SI, Rigas B. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996, 52:237-245. 10.1016/0006-2952(96)00181-5, 8694848.
41. Rice PL, Kelloff J, Sullivan H, Driggers LJ, Beard KS, Kuwada S, Piazza G, Ahnen DJ. Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells. Mol Cancer Ther 2003, 2:885-892.